[在4例复发性iTTP病例中,基于obinutuzumab加上葡萄糖皮质激素的联合治疗方案]
1Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Soochow Universtiy, Suzhou 215006, China.
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
|March 10, 2025
概括
与葡萄糖皮质类药物结合的奥比努祖马布有效地治疗复发性免疫血栓性血栓塞性紫外线 (iTTP). 这种安全治疗导致了所有患者的持续缓解,正常的ADAMTS13活性和负抑制剂.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 复发性免疫血栓性血栓性缺血性紫外线 (iTTP) 提出了重大治疗挑战,通常需要救援疗法.
- 以前的治疗方法,如rituximab和 bortezomib可能无法在多次复发的iTTP中实现持续缓解.
- 了解新型治疗组合对于管理耐火性iTTP病例至关重要.
研究的目的:
- 为了评估obinutuzumab加上基于葡萄糖皮质激素的治疗在复发的iTTP患者的疗效.
- 在研究的iTTP队列中评估这种组合治疗的安全性.
- 为了确定对用奥比努祖马布和葡萄皮质类药物治疗的患者的反应和缓解的持续时间.
主要方法:
- 对四名被诊断患有复发性iTTP的患者进行了回顾性分析.
- 治疗涉及奥比努图祖马布和基于葡萄糖皮质激素的疗法组合.
- 疗效终点包括临床缓解,ADAMTS13活性和抑制剂水平;对不良事件的安全性进行监测.
主要成果:
- 所有四名患者,有多次复发的病史和先前的治疗,都实现了临床缓解.
- 在治疗后,ADAMTS13活性正常化,所有患者的iTTP特异性抗体 (抑制剂) 无法检测到.
- 平均11个月的随访时间显示持续缓解,没有严重的不良事件.
结论:
- 与葡萄糖皮质激素治疗相结合的奥比努祖马布在治疗复发性iTTP时表现出显著的疗效.
- 这种治疗方法耐受性良好,没有报告严重不良事件.
- 这种组合为耐火性或复发性iTTP的患者提供了一个有希望和安全的选择.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
130
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
130
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
01:27Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
01:29Inflammatory Bowel Disease IV: Pharmacological Management
86
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
86